blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1993673

EP1993673 - INJECTABLE COMBINATION THERAPY FOR EYE DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.05.2018
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  26.05.2017
FormerGrant of patent is intended
Status updated on  24.05.2017
FormerExamination is in progress
Status updated on  25.04.2017
FormerGrant of patent is intended
Status updated on  15.12.2016
Most recent event   Tooltip26.06.2020Lapse of the patent in a contracting state
New state(s): CY		published on 29.07.2020  [2020/31]
Applicant(s)For all designated states
Apellis Pharmaceuticals, Inc.
6400 Westwind Way
Suite A
Crestwood, KY 40014 / US
[2017/51]
Former [2017/26]For all designated states
Potentia Pharmaceuticals, Inc.
201 East Jefferson Street, Suite 311
Louisville KY 40202 / US
Former [2008/48]For all designated states
Potentia Pharmaceuticals, Inc.
201 East Jefferson Street, Suite 311
Louisville KY 40202 / US
Inventor(s)01 / DESCHATELETS, Pascal
11031 Indian Legends, 202
Louisville, Kentucky 40241 / US
02 / OLSON, Paul
1202 Cherokee Road, Apt. 2
Louisville, KY 40204 / US
03 / FRANCOIS, Cedric
201 E. Jefferson St. 312
Louisville, kentucky 40202 / US
 [2017/26]
Former [2008/48]01 / DESCHATELETS, Pascal
11031 Indian Legends, 202
Louisville, Kentucky 40241 / US
02 / OLSON, Paul
1202 Cherokee Road
Louisville, KY 40204 / US
03 / FRANCOIS, Cedric
201 E. Jefferson St. 312
Louisville, kentucky 40202 / US
Representative(s)Lee, Nicholas John, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[N/P]
Former [2017/26]Lee, Nicholas John, et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ / GB
Former [2008/48]Cornish, Kristina Victoria Joy, et al
Kilburn & Strode 20 Red Lion Street London
WC1R 4PJ / GB
Application number, filing date07718112.119.01.2007
[2008/48]
WO2007US01649
Priority number, dateUS20060760974P19.01.2006         Original published format: US 760974 P
US2006054438906.10.2006         Original published format: US 544389
[2008/48]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007084765
Date:26.07.2007
Language:EN
[2007/30]
Type: A2 Application without search report 
No.:EP1993673
Date:26.11.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 26.07.2007 takes the place of the publication of the European patent application.
[2008/48]
Type: B1 Patent specification 
No.:EP1993673
Date:28.06.2017
Language:EN
[2017/26]
Search report(s)International search report - published on:EP15.05.2008
ClassificationIPC:A61P27/02, A61K38/08, A61K38/10, A61K38/12, A61K9/00, A61F9/00, A61K39/00, A61K38/00, A61K49/00, A61K47/06, A61K39/395, A61K31/00, A61K38/17
[2016/51]
CPC:
A61K38/08 (EP,US); C07K7/08 (US); A61K31/00 (EP,US);
A61K31/7105 (EP,US); A61K38/10 (EP,US); A61K38/12 (EP,US);
A61K38/17 (EP,US); A61K39/3955 (US); A61K49/0008 (US);
A61K9/0019 (US); A61K9/0048 (US); A61K9/0051 (EP,US);
A61P27/02 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/14 (EP); C07K16/28 (US); G01N33/6872 (US);
A61F9/0008 (EP,US); A61K2039/505 (US); A61K2039/507 (US);
A61K38/00 (EP,US); C07K2319/01 (US); G01N2333/4704 (US);
G01N2500/04 (US); G01N2500/20 (US) (-)
Former IPC [2008/48]A61P27/02, A61F2/14, A61K47/06, A61K39/395, A61K38/17, A61K31/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/26]
Former [2008/48]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:INJIZIERBARE KOMBINATIONSTHERAPIE FÜR AUGENERKRANKUNGEN[2008/48]
English:INJECTABLE COMBINATION THERAPY FOR EYE DISORDERS[2008/48]
French:TRAITEMENT COMBINATOIRE INJECTABLE DESTINE A DES TROUBLES OPHTALMIQUES[2008/48]
Entry into regional phase19.08.2008National basic fee paid 
19.08.2008Designation fee(s) paid 
19.08.2008Examination fee paid 
Examination procedure19.08.2008Examination requested  [2008/48]
27.10.2008Amendment by applicant (claims and/or description)
18.09.2012Despatch of a communication from the examining division (Time limit: M06)
28.03.2013Reply to a communication from the examining division
11.12.2013Despatch of a communication from the examining division (Time limit: M06)
29.09.2014Reply to a communication from the examining division
23.12.2014Despatch of a communication from the examining division (Time limit: M06)
30.07.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
09.10.2015Reply to a communication from the examining division
08.03.2016Despatch of a communication from the examining division (Time limit: M06)
01.09.2016Reply to a communication from the examining division
16.12.2016Communication of intention to grant the patent
20.04.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
25.04.2017Fee for grant paid
25.04.2017Fee for publishing/printing paid
23.05.2017Information about intention to grant a patent
23.05.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.09.2012
Opposition(s)29.03.2018No opposition filed within time limit [2018/23]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
09.10.2015Request for further processing filed
09.10.2015Full payment received (date of receipt of payment)
Request granted
19.10.2015Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
29.09.2014Request for further processing filed
29.09.2014Full payment received (date of receipt of payment)
Request granted
09.10.2014Decision despatched
Fees paidRenewal fee
30.01.2009Renewal fee patent year 03
25.01.2010Renewal fee patent year 04
25.01.2011Renewal fee patent year 05
25.01.2012Renewal fee patent year 06
25.01.2013Renewal fee patent year 07
27.01.2014Renewal fee patent year 08
27.01.2015Renewal fee patent year 09
27.01.2016Renewal fee patent year 10
27.01.2017Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.01.2007
CY28.06.2017
CZ28.06.2017
EE28.06.2017
LT28.06.2017
LV28.06.2017
MC28.06.2017
PT28.06.2017
RO28.06.2017
SI28.06.2017
SK28.06.2017
BG28.09.2017
IS28.10.2017
[2020/31]
Former [2020/27]HU19.01.2007
CZ28.06.2017
EE28.06.2017
LT28.06.2017
LV28.06.2017
MC28.06.2017
PT28.06.2017
RO28.06.2017
SI28.06.2017
SK28.06.2017
BG28.09.2017
IS28.10.2017
Former [2019/30]CZ28.06.2017
EE28.06.2017
LT28.06.2017
LV28.06.2017
MC28.06.2017
RO28.06.2017
SI28.06.2017
SK28.06.2017
BG28.09.2017
IS28.10.2017
Former [2018/39]CZ28.06.2017
EE28.06.2017
LT28.06.2017
LV28.06.2017
RO28.06.2017
SI28.06.2017
SK28.06.2017
BG28.09.2017
IS28.10.2017
Former [2018/11]CZ28.06.2017
EE28.06.2017
LT28.06.2017
LV28.06.2017
RO28.06.2017
SK28.06.2017
BG28.09.2017
IS28.10.2017
Former [2018/10]CZ28.06.2017
EE28.06.2017
LT28.06.2017
LV28.06.2017
RO28.06.2017
SK28.06.2017
BG28.09.2017
Former [2018/09]EE28.06.2017
LT28.06.2017
LV28.06.2017
BG28.09.2017
Former [2017/52]LT28.06.2017
LV28.06.2017
BG28.09.2017
Former [2017/49]LT28.06.2017
Cited inInternational search[Y]WO9630046  (GENENTECH INC [US]) [Y] 8,9,34,35 * the whole document *;
 [DY]US6051698  (JANJIC NEBOJSA [US], et al) [DY] 8-15,34-36 * the whole document *;
 [DY]US6319897  (LAMBRIS JOHN D [US], et al) [DY] 11-16,37-39 * the whole document *;
 [XY]US2005281861  (HUGHES PATRICK M [US], et al) [X] 1-10,18-36,40-65 * the whole document * [Y] 11-17,37-39;
 [Y]  - "Anti-VEGF Agents Useful in Age-Related Macular Degeneration", INTERNET CITATION, (20051015), URL: http://www.rsinewsrxreportingfrom.com/content.asp?myid=40&tid=365, (20070112), XP002414529 [Y] 1-65 * the whole document *
 [Y]  - MICHELS S ET AL, "TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB/LUCENTIS THERAPIE DER NEOVASKULAEREN ALTERSBEDINGTEN MAKULADEGENERATION MIT RANIBIZUMAB/LUCENTIS", KLINISCHE MONATSBLAETTER FUER AUGENHEILKUNDE, FERDINAND ENKE VERLAG, STUTTGART, DE, (200506), vol. 222, no. 6, ISSN 0023-2165, pages 480 - 484, XP009078844 [Y] 1-65 * the whole document *

DOI:   http://dx.doi.org/10.1055/s-2005-858315
 [DY]  - NG EUGENE W M ET AL, "TARGETING ANGIOGENESIS, THE UNDERLYING DISORDER IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION", CANADIAN JOURNAL OF OPHTHALMOLOGY, XX, XX, (200506), vol. 40, no. 3, ISSN 0008-4182, pages 352 - 368, XP009078843 [DY] 1-49 * the whole document *
 [Y]  - MURAT V KALAYOGLU, "Emerging Treatment Strategies For Age-Related Macular Degeneration", INTERNET CITATION, (20040630), URL: http://www.medcompare.com/spotlight.asp?spotlightid=62, (20070110), XP002414528 [Y] 1-65 * the whole document *
 [Y]  - "Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, (200305), vol. 110, no. 5, ISSN 0161-6420, pages 979 - 986, XP002366840 [Y] 1-65 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0161-6420(03)00085-X
 [Y]  - GRAGOUDAS EVANGELOS S ET AL, "Pegaptanib for neovascular age-related macular degeneration.", THE NEW ENGLAND JOURNAL OF MEDICINE 30 DEC 2004, (20041230), vol. 351, no. 27, ISSN 1533-4406, pages 2805 - 2816, XP002472472 [Y] 1-65 * the whole document *

DOI:   http://dx.doi.org/10.1056/NEJMoa042760
 [Y]  - AMBATI J ET AL, "Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies", SURVEY OF OPHTHALMOLOGY, SURVEY OF OPHTHALMOLOGY INC, XX, (2003), vol. 48, no. 3, ISSN 0039-6257, pages 257 - 293, XP002341326 [Y] 1-65 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0039-6257(03)00030-4
 [Y]  - ROSENFELD P, "An Update on Bevacizumab", INTERNET CITATION, (20051201), URL: http://www.revophth.com/index.asp?page=1_857.htm, (20070110), XP002414532 [Y] 1-65 * the whole document *
 [Y]  - MAKRIDES S C, "THERAPEUTIC INHIBITION OF THE COMPLEMENT SYSTEM", PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, (1998), vol. 50, no. 1, ISSN 0031-6997, pages 59 - 87, XP001055179 [Y] 11-17,37-39 * page 71, column R, paragraph 2 - page 73, column R, paragraph 2; table 5 *
 [Y]  - JOHNSON L V ET AL, "Complement activation and inflammatory processes in drusen formation and age related macular degeneration", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD., LONDON, GB, (200112), vol. 73, no. 6, ISSN 0014-4835, pages 887 - 896, XP002386744 [Y] 11-17,37-39 * the whole document *

DOI:   http://dx.doi.org/10.1006/exer.2001.1094
 [Y]  - RAISLER B J ET AL, "Drusen complement components C3a and C5a promote choroidal neovascularization", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (2005), Database accession no. PREV200600053073, XP002472473 [Y] 11-17,37-39 * abstract *
    [ ] - IOVS, ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPHTHALM OLOGY; FT LAUDERDALE, FL, USA; MAY 01 -05, 2005, (2005), vol. 46, no. Suppl. S, ISSN 0146-0404, page 1214
 [Y]  - MORIKIS O ET AL, "Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches", BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, (200402), vol. 32, no. 1, ISSN 0300-5127, pages 28 - 32, XP002455138 [Y] 11-17,37-39 * abstract *

DOI:   http://dx.doi.org/10.1042/BST0320028
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.